Arrowstreet Capital
CRL icon

Arrowstreet Capital’s Charles River Laboratories CRL Stock Holding History

Arrowstreet Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.2M Sell
278,558
-458,472
-62% -$81.6M 0.03% 483
2026
Q1 		$127M Sell
737,030
-99,210
-12% -$18.4M 0.07% 268
2025
Q4 		$167M Buy
836,240
+66,803
+9% +$12.1M 0.1% 208
2025
Q3 		$120M Buy
769,437
+190,828
+33% +$30.3M 0.08% 238
2025
Q2 		$87.8M Buy
578,609
+225,027
+64% +$30M 0.06% 286
2025
Q1 		$53.2M Buy
+353,582
New +$59.3M 0.04% 360
2022
Q1 		– Sell
-46,901
Closed -$17.7M – 1247
2021
Q4 		$17.7M Sell
46,901
-1,099
-2% -$427K 0.02% 514
2021
Q3 		$19.8M Buy
+48,000
New +$19.9M 0.02% 535
2020
Q3 		– Sell
-2,800
Closed -$488K – 2357
2020
Q2 		$488K Buy
+2,800
New +$447K ﹤0.01% 1971
2019
Q4 		– Sell
-4,900
Closed -$649K – 1773
2019
Q3 		$649K Sell
4,900
-169,559
-97% -$22.7M ﹤0.01% 1263
2019
Q2 		$24.8M Buy
174,459
+8,325
+5% +$1.13M 0.06% 320
2019
Q1 		$24.1M Buy
166,134
+104,834
+171% +$13.8M 0.06% 315
2018
Q4 		$6.94M Buy
+61,300
New +$7.68M 0.02% 507
2018
Q3 		– Sell
-99,847
Closed -$11.2M – 1113
2018
Q2 		$11.2M Sell
99,847
-93,167
-48% -$10.1M 0.03% 400
2018
Q1 		$20.6M Sell
193,014
-231,466
-55% -$24.9M 0.05% 312
2017
Q4 		$46.5M Buy
424,480
+253,180
+148% +$27.6M 0.11% 188
2017
Q3 		$18.5M Buy
171,300
+167,900
+4,938% +$17.2M 0.05% 293
2017
Q2 		$344K Buy
+3,400
New +$313K ﹤0.01% 926
2016
Q4 		– Sell
-56,600
Closed -$4.72M – 1803
2016
Q3 		$4.72M Buy
+56,600
New +$4.74M 0.02% 660

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Arrowstreet Capital's CRL Position: Q2 2026 in Review

Arrowstreet Capital reduced its Charles River Laboratories (CRL) stake by 62% in Q2 2026, selling an estimated $81.6M and leaving 278,558 shares worth $63.2M. The position accounts for 0.03% of the portfolio, ranked #483.

Arrowstreet Capital first reported a position in CRL in Q3 2016 and has held it in 19 quarters since. The position peaked at $167M in Q4 2025. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Arrowstreet Capital held 278,558 shares of Charles River Laboratories worth $63.2M as of Q2 2026.
  • Arrowstreet Capital sold 458,472 Charles River Laboratories shares in Q2 2026, an estimated $81.6M.
  • Charles River Laboratories made up 0.03% of Arrowstreet Capital's portfolio in Q2 2026, its #483 holding.
  • Arrowstreet Capital first reported a position in Charles River Laboratories in Q3 2016 and has held it in 19 quarters since.
  • Arrowstreet Capital's Charles River Laboratories position peaked at $167M in Q4 2025.
  • 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.